BRIEF-Hemispherx Biopharma gets approval of NDA to treat chronic fatigue syndrome

martes 23 de agosto de 2016 08:39 GYT

Aug 23 (Reuters) - Hemispherx Biopharma Inc:

* Received approval of NDA in argentine republic for treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome

* Says rintatolimod will be marketed by GP Pharm, Hemispherx's commercial partner in Latin America Source text for Eikon: Further company coverage: